2021 Revenues ($USD) : $10,310,000,000
2021 R&D spend : $1,000,000,000
2021 Number of Employees : 25,000
Fiscal Year End : 6/30/2021
Leader : CEO Paul Perreault

CSL Behring specializes in developing plasma-derived and recombinant therapies for a range of rare and serious diseases. The company is the result of the merger between Behringwerke, founded in 1904 in Germany, and Commonwealth Serum Laboratories (CSL), founded in Australia in 1916. CSL Behring was created in 2007. Its headquarters are in King of Prussia, Pennsylvania, with parent company CSL's headquarters in Australia. In 2021, CSL Behring had strong sales of its core portfolio products, including Hizentra, a subcutaneous immunoglobulin treatment for primary immune deficiency, which was up 15%. Overall, its core immunoglobulin business grew 3%. The company’s influenza products saw especially swift growth, with sales of seasonal influenza vaccines up 41%. —BB